MedPath

Serine

Generic Name
Serine
Brand Names
Hepatamine 8, Clinimix 2.75/5, Clinimix E 2.75/5, Clinisol 15, Premasol, Procalamine 3, Plenamine, Primene, Periolimel, Freamine III 10, Trophamine 10 %, Aminosyn II 7 %, Aminosyn-PF 7%, Prosol, Sulfite-free, Travasol 10, Olimel, Freamine 6.9
Drug Type
Small Molecule
Chemical Formula
C3H7NO3
CAS Number
56-45-1
Unique Ingredient Identifier
452VLY9402
Background

A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from glycine or threonine. It is involved in the biosynthesis of purines; pyrimidines; and other amino acids.

Indication

Used as a natural moisturizing agent in some cosmetics and skin care products.

Associated Conditions
Iron Deficiency Anemia (IDA), Iron Deficiency (ID)
Associated Therapies
Amino acid supplementation
Clinical Trials
Related News

Hereditary Sensory Neuropathy Serine Trial

Phase 2
Recruiting
Conditions
Hereditary Sensory Neuropathy Type I
Interventions
Drug: Placebo
Drug: L-serine
First Posted Date
2023-11-02
Last Posted Date
2023-11-02
Lead Sponsor
University College, London
Target Recruit Count
50
Registration Number
NCT06113055
Locations
🇬🇧

University College London, London, United Kingdom

Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS)

Phase 2
Terminated
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Drug: L-Serine
First Posted Date
2018-07-09
Last Posted Date
2023-09-07
Lead Sponsor
Elijah W. Stommel
Target Recruit Count
43
Registration Number
NCT03580616
Locations
🇺🇸

Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States

Phase IIa L-serine Trial for eAD

Phase 2
Terminated
Conditions
Alzheimer Disease
Interventions
Other: Placebo Gummy
Drug: L-Serine
First Posted Date
2017-02-23
Last Posted Date
2024-07-03
Lead Sponsor
Aleksandra Stark
Target Recruit Count
29
Registration Number
NCT03062449
Locations
🇺🇸

Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States

Determining the Safety of L-serine in ALS

Phase 1
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Drug: L-Serine
First Posted Date
2013-04-19
Last Posted Date
2015-07-30
Lead Sponsor
Phoenix Neurological Associates, LTD
Target Recruit Count
20
Registration Number
NCT01835782
Locations
🇺🇸

Phoenix Neurological Associates, Phoenix, Arizona, United States

🇺🇸

Forbes Norris MDA/ALS Research Center, San Francisco, California, United States

L-Serine Supplementation in Hereditary Sensory Neuropathy Type 1

Phase 1
Completed
Conditions
Hereditary Sensory and Autonomic Neuropathy Type I
Interventions
Drug: placebo
Drug: L-serine
First Posted Date
2012-11-27
Last Posted Date
2018-09-12
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
18
Registration Number
NCT01733407
Locations
🇺🇸

UMass Medical Center, Worcester, Massachusetts, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy